| EN

Enlighten:Bendamustine Hydrochloride for Injection

Enlighten:Bendamustine Hydrochloride for Injection


  1. Chronic Lymphocytic Leukemia (CLL): for the treatment of patients with chronic lymphocytic leukemia. (Efficacy relative to first-line therapies other than chlorambucil has not been established.)

  2. Non-Hodgkin Lymphoma (NHL): for the treatment of patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or after treatment with rituximab or a rituximab-containing regimen.

The only bendamustine approved for indication of both CLL and B-cell NHL in China currently. In 2020, guidelines published by the Chinese Society of Clinical Oncology (CSCO) and National Comprehensive Cancer Network (NCCN) have recommended bendamustine as the first- and second- line treatment of multiple subtypes of B-cell lymphoma.